These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32317663)

  • 1. Exploiting evolutionary steering to induce collateral drug sensitivity in cancer.
    Acar A; Nichol D; Fernandez-Mateos J; Cresswell GD; Barozzi I; Hong SP; Trahearn N; Spiteri I; Stubbs M; Burke R; Stewart A; Caravagna G; Werner B; Vlachogiannis G; Maley CC; Magnani L; Valeri N; Banerji U; Sottoriva A
    Nat Commun; 2020 Apr; 11(1):1923. PubMed ID: 32317663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer.
    Müller N; Lorenz C; Ostendorp J; Heisel FS; Friese UP; Cartolano M; Plenker D; Tumbrink H; Heimsoeth A; Baedeker P; Weiss J; Ortiz-Cuaran S; Büttner R; Peifer M; Thomas RK; Sos ML; Berg J; Brägelmann J
    Cancer Res; 2023 Aug; 83(15):2471-2479. PubMed ID: 37289018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.
    Murtaza M; Dawson SJ; Tsui DW; Gale D; Forshew T; Piskorz AM; Parkinson C; Chin SF; Kingsbury Z; Wong AS; Marass F; Humphray S; Hadfield J; Bentley D; Chin TM; Brenton JD; Caldas C; Rosenfeld N
    Nature; 2013 May; 497(7447):108-12. PubMed ID: 23563269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical analysis of gefitinib resistance of lung adenocarcinoma caused by MET amplification.
    Ito T; Kumagai Y; Itano K; Maruyama T; Tamura K; Kawasaki S; Suzuki T; Murakami Y
    Biochem Biophys Res Commun; 2019 Apr; 511(3):544-550. PubMed ID: 30824185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hsa-miR-4271 downregulates the expression of constitutive androstane receptor and enhances in vivo the sensitivity of non-small cell lung cancer to gefitinib.
    Wang C; Ding S; Sun B; Shen L; Xiao L; Han Z; Huang H
    Pharmacol Res; 2020 Nov; 161():105110. PubMed ID: 32755614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
    Liu Z; Gao W
    Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational platform for modelling, analysis, and prediction of anti-EGFR drug resistance for lung cancer.
    Yan H; Zhu GY; Wong M; Lee V
    Hong Kong Med J; 2019 Dec; 25 Suppl 9(6):40-42. PubMed ID: 31889035
    [No Abstract]   [Full Text] [Related]  

  • 9. Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Sin TK; Wang F; Meng F; Wong SC; Cho WC; Siu PM; Chan LW; Yung BY
    Int J Mol Sci; 2016 Feb; 17(2):237. PubMed ID: 26891293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
    Dimou A; Nasarre C; Peterson YK; Pagano R; Gooz M; Nasarre P; Drabkin HA; Armeson KE; Gibney BC; Gemmill RM; Denlinger CE
    J Thorac Cardiovasc Surg; 2021 Aug; 162(2):463-473. PubMed ID: 32653291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. let‑7 and miR‑17 promote self‑renewal and drive gefitinib resistance in non‑small cell lung cancer.
    Yin J; Hu W; Pan L; Fu W; Dai L; Jiang Z; Zhang F; Zhao J
    Oncol Rep; 2019 Aug; 42(2):495-508. PubMed ID: 31233201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer.
    Dhawan A; Nichol D; Kinose F; Abazeed ME; Marusyk A; Haura EB; Scott JG
    Sci Rep; 2017 Apr; 7(1):1232. PubMed ID: 28450729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative Evolutionary Paths to Bacterial Antibiotic Resistance Cause Distinct Collateral Effects.
    Barbosa C; Trebosc V; Kemmer C; Rosenstiel P; Beardmore R; Schulenburg H; Jansen G
    Mol Biol Evol; 2017 Sep; 34(9):2229-2244. PubMed ID: 28541480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating evolutionary dynamics into cancer therapy.
    Gatenby RA; Brown JS
    Nat Rev Clin Oncol; 2020 Nov; 17(11):675-686. PubMed ID: 32699310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitor of ghrelin receptor reverses gefitinib resistance in lung cancer.
    Li X; Zhao X; Li C; Liu S; Yan F; Teng Y; Feng J; Miao D
    Hum Cell; 2019 Jul; 32(3):360-366. PubMed ID: 31020605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
    Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental Determination of Cancer Drug Targets with Independent Mechanisms of Resistance.
    Bland AR; Shrestha N; Berry M; Wilson C; Ashton JC
    Curr Cancer Drug Targets; 2022; 22(2):97-107. PubMed ID: 34994310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway.
    Wang MS; Han QS; Jia ZR; Chen CS; Qiao C; Liu QQ; Zhang YM; Wang KW; Wang J; Xiao K; Ding XS
    Acta Pharmacol Sin; 2022 Jan; 43(1):167-176. PubMed ID: 33772142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies.
    Foo J; Michor F
    PLoS Comput Biol; 2009 Nov; 5(11):e1000557. PubMed ID: 19893626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.